This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2024 Jun 1;130(11):1903.

doi: 10.1002/cncr.35346.

FDA approves first immunotherapy drug for nasopharyngeal carcinoma

Mary Beth Nierengarten

PMID: 38757625
DOI: 10.1002/cncr.35346

Free article

FDA approves first immunotherapy drug for nasopharyngeal carcinoma

Mary Beth Nierengarten. Cancer. 2024.

Free article

. 2024 Jun 1;130(11):1903.

doi: 10.1002/cncr.35346.

Author

Mary Beth Nierengarten

PMID: 38757625
DOI: 10.1002/cncr.35346

No abstract available

PubMed Disclaimer

Similar articles

Immunotherapy for Nasopharyngeal Carcinoma: The Earlier the Better.
Bossi P, Gurizzan C, Chan A. Bossi P, et al. JAMA. 2023 Nov 28;330(20):1954-1955. doi: 10.1001/jama.2023.22465. JAMA. 2023. PMID: 38015229 No abstract available.
Letter to the Editor, "Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma".
Dharmalingam Jothinathan MK. Dharmalingam Jothinathan MK. Oral Oncol. 2024 Sep;156:106948. doi: 10.1016/j.oraloncology.2024.106948. Epub 2024 Jul 13. Oral Oncol. 2024. PMID: 39004023 No abstract available.
FDA approves sublingual hay fever immunotherapeutic.
Riedmann EM. Riedmann EM. Hum Vaccin Immunother. 2014;10(6):1428. Hum Vaccin Immunother. 2014. PMID: 25396228 No abstract available.
Induction treatment prior to chemoradiotherapy in nasopharyngeal carcinoma: triplet or doublet chemotherapy?
Hennessy MA, Morris PG. Hennessy MA, et al. Anticancer Drugs. 2020 Feb;31(2):97-100. doi: 10.1097/CAD.0000000000000867. Anticancer Drugs. 2020. PMID: 31815764 Review.
Immunotherapeutic approaches in nasopharyngeal carcinoma.
Chow JC, Ngan RK, Cheung KM, Cho WC. Chow JC, et al. Expert Opin Biol Ther. 2019 Nov;19(11):1165-1172. doi: 10.1080/14712598.2019.1650910. Epub 2019 Aug 13. Expert Opin Biol Ther. 2019. PMID: 31361154 Review.

See all similar articles

Cited by

The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis.
Guo Q, Dong D, Dang Z, Huang S, Qiao X, Zhang B, Zhao Y. Guo Q, et al. PLoS One. 2025 Jun 20;20(6):e0326216. doi: 10.1371/journal.pone.0326216. eCollection 2025. PLoS One. 2025. PMID: 40540517 Free PMC article.

References

1. Toripalimab becomes first immunotherapy drug approved for nasopharyngeal cancer. National Cancer Institute. January 3, 2024. https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-toripal... Becomes First Immunotherapy Drug Approved for Nasopharyngeal Cancer,-Subscribe&text=Imaging scans of a person,doses received during earlier treatment
1. Mai HQ, Chen QY, Chen D, et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER‐02 randomized clinical trials. JAMA. 2023;330(20):1961‐1970. doi:10.1001/jama.2023.20181
1. Wang FH, Wei XL, Feng J, et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS‐02). J Clin Oncol. 2021;39(7):704‐712. doi:10.1200/JCO.20.02712

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley